About us
At PackGene, we are committed to breaking barriers in gene therapy by providing comprehensive and cost-effective AAV, lentivirus, mRNA and plasmid solutions.
Learn More
-
1,000 +
Clients globally
From biopharmaceutical companies and research institutions -
50,000 +
Projects delivered
From research to GMP production -
120,000 sqf
GMP facility
Viral Vector production
고객 평가
Leading technology and global reputation
정보 자료
뉴스이벤트인용 논문
-
AAV Gene Therapy in Ocular Diseases
Apr 18 2025 -
uniQure's AMT-130 Receives FDA Breakthrough Therapy Designation for Huntington's Disease
Apr 17 2025 -
Rare Diseases in Malaysia: An Overlooked Crisis Affecting One Million
Apr 17 2025 -
French Biotech Brink Therapeutics Secures €3.5M to Pioneer Next-Generation Gene Editing with Recombinases
Apr 17 2025 -
Glycomine Secures $115M Series C to Advance PMM2-CDG Therapy
Apr 16 2025 -
Lexeo Reports Promising Interim Phase 1/2 Results for LX2006 in FA Cardiomyopathy, Plans Registrational Study
Apr 15 2025
-
Coming
AACR Annual Meeting 2025, Chicago, April 25-30
Apr 15 2025 -
Ing
PackGene at the Cell & Gene Meeting on the Med 2025
Apr 15 2025 -
Past
Advanced Therapies London (ExCel, London, Mar 18-19, 2025)
Mar 18 2025 -
Past
Rare Disease Day (Feb, 28, 2025) – Breaking Barriers in Rare Disease Gene Therapy
Feb 28 2025 -
Past
PMWC (Silicon Valley, CA, Feb 5-7, 2025)
Feb 05 2025 -
Past
Advanced Therapies Week (Dallas, TX, Jan 20-23, 2025)
Jan 20 2025
